MedicalResearch.com |

How Stimulants Affect the Brain’s Reward Pathway

[caption id="attachment_70329" align="aligncenter" width="500"]

Photo courtesy of Freepik[/caption] Stimulants are substances that increase brain activity, heightening alertness, energy, and focus. Common examples include caffeine, nicotine, and amphetamines. This article explores how these compounds activate the brain’s reward pathway and produce effects that can range from a gentle lift in mood to an intense short-lived “buzz” that reinforces repeated use.

Understanding the Reward Pathway

The brain’s reward pathway, known as the mesolimbic dopamine system, involves key regions such as the ventral tegmental area, nucleus accumbens, and prefrontal cortex. This network reinforces pleasurable behaviors by releasing dopamine which is a neurotransmitter linked to motivation and reward. While natural activities like eating or socializing activate this system moderately, stimulants can hijack it. These trigger a much stronger and faster dopamine release. This heightened response can make the experience more compelling that encourages repeated use and increases the potential for dependence over time.

Addiction, Author Interviews, Cannabis / 05.08.2024

After the legalization of recreational cannabis, there were no significant increases in rates of prescription stimulant use in the U.S

MedicalResearch.com Interview with: [caption id="attachment_62745" align="alignleft" width="130"]

Luke Cavanah[/caption] Luke Cavanah, BS Department of Medical Education Geisinger Commonwealth School of Medicine Scranton, PA 18509 MedicalResearch.com: What is the background for this study? Response: Amphetamine, lisdexamfetamine, and methylphenidate, are first-line treatments for attention-deficit hyperactivity disorder (ADHD) and are classified as Schedule II stimulants due to their risk of addiction. (1–3) There has been high and increasing use and misuse of these medications with inadequate explanation. (4) Since chronic cannabis use can result in similar cognitive effects as ADHD 5–7, we wondered if more stimulants were prescribed for what appeared to be ADHD but was a consequence of chronic cannabis use. In other words, has the legalization of cannabis contributed to this inadequately explained increase in stimulant use? A recent study by our lab group that looked at the slopes of stimulant distribution rates over time -- before and after medical cannabis legalization -- did not support this.(8) Given the prevalence and increasing legalization of recreational cannabis, we wanted to determine how slopes of stimulant distribution rates compared before and after recreational cannabis legalization.

Author Interviews, Cannabis / 30.08.2023

No Observed Increase in Prescription Stimulant Use After Legalization of Medical Marijuana

Luke Cavanah, BS Geisinger Commonwealth School of Medicine Scranton, PA

MedicalResearch.com Interview with: [caption id="attachment_60828" align="alignleft" width="172"]

Luke Cavanah[/caption] Luke Cavanah, BS Geisinger Commonwealth School of Medicine Scranton, PA MedicalResearch.com: What is the background for this study? Response: It is well-known that schedule II stimulants, which are those that are highly addictive and include amphetamine, methylphenidate, and lisdexamfetamine, have had increasing use and misuse in the US. Despite understanding the presence of this phenomenon, the reason for it is poorly understood. The purpose of this study was to see if rising rates of schedule II stimulants are related to the legalization of medical marijuana. We were interested in this because schedule II stimulants are primarily used as the treatment for attention-deficit hyperactivity disorder (ADHD), chronic cannabis use has been demonstrated to cause neurocognitive deficits resembling that of ADHD, and the conditions have been shown to affect similar brain regions.

Author Interviews, Methamphetamine / 06.01.2019

Prescription Stimulant Use Varies Widely Across US

Brian J. Piper, PhD, MS Assistant Professor of Neuroscience Department of Basic Sciences, Geisinger Commonwealth School of Medicine, Scranton PA 18509

MedicalResearch.com Interview with: [caption id="attachment_43644" align="alignleft" width="200"]

Brian J. Piper, PhD, MS Department of Basic Sciences Geisinger Commonwealth School of Medicine Scranton, PA 18509

Dr. Piper[/caption] Brian J. Piper, PhD, MS Assistant Professor of Neuroscience Department of Basic Sciences, Geisinger Commonwealth School of Medicine, Scranton PA 18509 MedicalResearch.com: What is the background for this study? Response: The U.S. accounts for five percent of the world population but more than 92 percent of the world’s spending on pharmacotherapies for Attention Deficit Hyperactivity Disorder (ADHD). According to the 2011 National Survey of Children’s Health, ADHD increased to 11.0 percent of U.S. children, seven percent of girls and 15 percent of boys. Interestingly, ADHD rates were much lower among Hispanic children. The 2013 revision to the Diagnostic and Statistical Manual of Mental Disorders broadened the criteria such that it became easier to diagnose adult ADHD. Together, we hypothesized that use of amphetamine (Adderall), methylphenidate (Ritalin), and lisdexamfetamine (Vyvanse) would be increasing. We also predicted that there would be some regional differences in stimulant use.

Author Interviews, JAMA, Supplements / 23.10.2018

Banned Stimulants Remain in Supplements, Despite FDA Efforts to Remove Them

“Pills Vitamins Macro April 22, 2012 4” by Steven Depolo is licensed under CC BY 2.0

One of the most concerning findings was that one stimulant appeared in the supplements analyzed only after the FDA warned...

ADHD, Author Interviews, Brigham & Women's - Harvard, Heart Disease, JAMA, OBGYNE / 14.12.2017

Small Increased Risk of Cardiac Birth Defects With ADHD Drug During Pregnancy

MedicalResearch.com Interview with: [caption id="attachment_27170" align="alignleft" width="179"]

Krista F. Huybrechts, M.S., Ph.D. Assistant Professor of Medicine at Harvard Medical School Epidemiologist in the Division of Pharmacoepidemiology and Pharmacoeconomics Brigham and Women’s Hospital. Boston, MA 02120

Dr. Krista Huybrechts[/caption] Krista F. Huybrechts, MS PhD Assistant Professor of Medicine Division of Pharmacoepidemiology and Pharmacoeconomics Brigham and Women's Hospital Harvard Medical School Boston, MA 02120 MedicalResearch.com: What is the background for this study? What are the main findings? Response: In recent years, use of stimulant medications in adults, including women of reproductive age, has increased substantially. However, data regarding the safety of stimulant medications in early pregnancy are sparse and conflicting. For example, two recent cohort studies failed to detect an association between use of methylphenidate in early pregnancy and overall or cardiac malformations, while another found an 81% increased risk of cardiac malformations, although the estimate was imprecise. Given the rapidly increasing use of stimulant medications during pregnancy and among women of reproductive age who may become pregnant inadvertently, there is an urgent need to better understand their safety.